Researchers at MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair achieved significant tumor regression in mouse models of small cell lung cancer, suggesting a promising new approach for treating patients with this aggressive cancer.
Grants are flowing out of NCI again to beat the fiscal-year end deadline and some cancer researchers are starting to feel cautiously optimistic about the future.
